BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 20451754)

  • 1. Re: Billis et al.: Does the type of prostatic atrophy influence the association of extent of atrophy in needle biopsies and serum prostate-specific antigen levels? (Urology 2009;74:1111-1115).
    Papatsoris A; Albanis S; Deliveliotis C
    Urology; 2010 May; 75(5):1239; author reply 1240. PubMed ID: 20451754
    [No Abstract]   [Full Text] [Related]  

  • 2. Does the type of prostatic atrophy influence the association of extent of atrophy in needle biopsies and serum prostate-specific antigen levels?
    Billis A; Meirelles L; Freitas LL; Magna LA; Ferreira U
    Urology; 2009 Nov; 74(5):1111-5. PubMed ID: 19773041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between immunohistochemical patterns and serum levels of PSA and PSAP in prostatic pathology: evaluation of 198 prostatic fine needle biopsies.
    Vitali A; Ardoino S; Durante P; Ferro MA; Li Causi F; Parodi C; Sanguineti G; Gaffuri M; Paerachino M; Salvadori RP
    Anticancer Res; 1994; 14(4A):1503-7. PubMed ID: 7526771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extent of prostatic atrophy in needle biopsies and serum PSA levels: is there an association?
    Billis A; Meirelles LR; Magna LA; Baracat J; Prando A; Ferreira U
    Urology; 2007 May; 69(5):927-30. PubMed ID: 17482936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: Kim et al.: detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/ml (Urology 2010;76:919-922).
    Shenoy SP; Marla PK; Adappa KK
    Urology; 2011 Apr; 77(4):1013-4; author reply 1014. PubMed ID: 21477737
    [No Abstract]   [Full Text] [Related]  

  • 6. Repeat prostate needle biopsy: who needs it?
    Ellis WJ; Brawer MK
    J Urol; 1995 May; 153(5):1496-8. PubMed ID: 7536254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
    Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
    Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial comment on: Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us?
    Stanislaus P; Seitz M
    Eur Urol; 2009 Apr; 55(4):909-10. PubMed ID: 18485577
    [No Abstract]   [Full Text] [Related]  

  • 9. Biopsies for "normal" PSA? Certain relatively young, healthy men with PSA levels below 4 should consider having a biopsy.
    Gerber GS
    Health News; 2004 Jul; 10(7):4-5. PubMed ID: 15239153
    [No Abstract]   [Full Text] [Related]  

  • 10. [The clinical usefulness of routine biopsy of the transition zone in the diagnosis of prostate cancer].
    Morote Robles J; López Pacios M; Encabo Duró G; de Torres Ramírez I
    Actas Urol Esp; 1999; 23(7):583-6. PubMed ID: 10488612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atrophy in prostate needle biopsy cores and its relationship to prostate cancer incidence in screened men.
    Postma R; Schröder FH; van der Kwast TH
    Urology; 2005 Apr; 65(4):745-9. PubMed ID: 15833520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values.
    Keetch DW; Catalona WJ
    J Urol; 1995 Nov; 154(5):1795-7. PubMed ID: 7563349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer.
    Schoenfield L; Jones JS; Zippe CD; Reuther AM; Klein E; Zhou M; Magi-Galluzzi C
    BJU Int; 2007 Apr; 99(4):770-4. PubMed ID: 17233800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA.
    Stamey TA
    BJU Int; 2004 Nov; 94(7):963-4. PubMed ID: 15541106
    [No Abstract]   [Full Text] [Related]  

  • 15. Intensifying the saturation biopsy technique for detecting prostate cancer after previous negative biopsies: a step in the wrong direction.
    Bott S; Langley S; Hindley R; Montgomery B
    BJU Int; 2009 Mar; 103(5):701. PubMed ID: 19226428
    [No Abstract]   [Full Text] [Related]  

  • 16. Can perineural invasion on prostate needle biopsy predict prostate specific antigen recurrence after radical prostatectomy?
    de la Taille A; Rubin MA; Bagiella E; Olsson CA; Buttyan R; Burchardt T; Knight C; O'Toole KM; Katz AE
    J Urol; 1999 Jul; 162(1):103-6. PubMed ID: 10379750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial comment on: decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial.
    Finney Rutten LJ
    Eur Urol; 2008 Jun; 53(6):1193. PubMed ID: 17709172
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?
    Gosselaar C; Roobol MJ; Schröder FH
    BJU Int; 2005 Feb; 95(2):231-7. PubMed ID: 15667646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of percent free prostate specific antigen as a predictor of prostate cancer detection on repeat biopsy.
    Uemura H; Nakamura M; Hasumi H; Sugiura S; Fujinami K; Miyoshi Y; Yao M; Kubota Y
    Int J Urol; 2004 Jul; 11(7):494-500. PubMed ID: 15242358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of free prostate-specific antigen measurement in prostate-specific antigen screening for prostate cancer.
    Johnson L
    Clin Prostate Cancer; 2002 Dec; 1(3):142-4. PubMed ID: 15046688
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.